Brazil Cancels Bharat Biotech's Covaxin Clinical Studies Due To Controversy

Following the controversy related to the deal with the Brazilian government for the supply of 20 million doses of vaccine led to the suspension of clinical studies of 'Bharat Bio-Tech Covaxin.’ It thus terminated Bharat Biotech’s agreement with its partner. The MoU signed with Precisa Medicamentos and Envixia Pharmaceuticals LLC for its Covid-19 vaccine Covaxin for the Brazilian market was cancelled by Bharat Biotech on July 23.